<DOC>
	<DOCNO>NCT01854645</DOCNO>
	<brief_summary>The overall objective study assess efficacy safety treatment PT003 ( GFF MDI ) , PT005 ( FF MDI ) , PT001 ( GP MDI ) , open-label tiotropium bromide inhalation powder compare Placebo MDI 24 week subject moderate severe COPD .</brief_summary>
	<brief_title>Efficacy Safety PT003 , PT005 , PT001 Subjects With Moderate Very Severe Chronic Obstructive Pulmonary Disease ( COPD ) ; ( PINNACLE 1 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Key Male female subject least 40 year age old 80 Visit 1 . Subjects establish clinical history COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) Current former smoker history least 10 packyears cigarette smoking . Average f 60 30 min predose FEV1 assessment must &lt; 80 % predict normal value calculate use National Health Nutrition Examination Survey ( NHANES ) III reference equation . Subjects willing , opinion investigator , able adjust current COPD therapy require protocol Key Significant diseases COPD , i.e . disease condition , opinion investigator , may put patient risk participation study may influence either result study subject 's ability participate study Current diagnosis asthma alpha1 antitrypsin deficiency Other active pulmonary disease active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , idiopathic interstitial pulmonary fibrosis , primary pulmonary hypertension , uncontrolled sleep apnea Hospitalized due poorly control COPD within 3 month prior screen Screening Period Poorly control COPD , define acute worsen COPD require treatment oral corticosteroid antibiotic within 6 week prior screen Screening Period Lower respiratory tract infection require antibiotic within 6 week prior screen Screening Period Unstable ischemic heart disease , leave ventricular failure , document myocardial infarction within 12 month enrollment . Recent history acute coronary syndrome , percutaneous coronary intervention , coronary artery bypass graft within past three month Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) Class III/IV ) Clinically significant abnormal 12lead ECG Abnormal liver function test define aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , total bilirubin ≥ 1.5 time upper limit normal Visit 1 repeat test Cancer complete remission least five year History hypersensitivity β2agonists , glycopyrronium muscarinic anticholinergic , lactose/milk protein component MDI Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>